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Obstructive sleep apnea (OSA) and periodic limb movements during sleep (PLMs) are sleep-related
disorders with a high prevalence in type 2 diabetes. Commonly OSA is considered as a consequence of
obesity, but several previous studies have shown the presence of OSA in non-obese diabetic patients. A
previous study showed higher PLMs prevalence in patients with type 2 diabetes, compared to age-
matched controls. We speculated that both OSA and PLMs may reﬂect the presence of diabetic auto-
nomic neuropathy. To test this hypothesis, we compared a group of 112 non-obese patients with type 2
diabetes with 66 age-, sex-, and body mass index- matched nondiabetic patients. Both groups have been
investigated through a set of tests including the Epworth Sleepiness Scale, polysomnography, and the
Orthostatic Grading Scale (OGS), a questionnaire to assess the degree of autonomic dysfunction. Diabetic
patients with OSA and PLMs scored higher on the OGS than controls. Our results conﬁrm that both OSA
and PLMs are related to dysautonomy and may be unrelated to obesity in type 2 diabetes patients.
 2014 The Authors. Published by Elsevier Inc. All rights reserved.Introduction
Sleep duration and quality modulates metabolic, endocrine, and
cardiovascular functions [37]. Alterations in the control of blood
sugar may gradually lead to serious dysregulation of sleep control
and vice-versa.
A dramatic increase in the incidence of diabetes and obesity
appears to develop simultaneously with decreased self-reported
sleep duration; this may indicate a close relationship between
diabetes and sleep disorder [36,39]. The Sleep Heart Health Study
showed that diabetes patients had less time spent on REM sleep
and more breathing episodes vs. people without diabetes [30]. In
Type 2 diabetes, sleep disturbances are held to be common; theyBY-NC-ND license (http://
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Published by Elsevier Inc. All righthave been attributed to impaired glucose metabolism and general
physical distress [16].
Obesity may constitute a risk factor for obstructive sleep apnea
(OSA) [24], which is in turn associated with greater insulin resis-
tance [13,29]. Both longer and shorter sleep duration increase the
odds of having a metabolic syndrome [25], and poor sleep quality,
as assessed with the Pittsburgh Sleep Quality Index, was found to
negatively affect cardiovascular risk markers, like systolic blood
pressure and blood lipid concentrations in type 2 diabetes patients
[41]; in particular, severe OSA was found to be associated with
greater cardiovascular risk and mortality, while OSA was positively
associatedwith diabetes [10]. However, OSA and type 2 diabetes are
associated with each other bidirectionally, and the presence of one
may increase the risk of the other [1]. Diabetic autonomic neu-
ropathy may be associated with increased OSA [7,44]. West et al.
[44] showed a high prevalence of OSA in menwith type 2 diabetes,
concluding that diabetes itself may be a signiﬁcant, independent
contributor to the risk of OSA.
Recently Rizzi et al. [31] detected a greater prevalence of peri-
odic limb movements during sleep (PLMS) in type 2 diabetes pa-
tients, compared age-matched healthy volunteers, probably due to
an involvement of the sympathetic nervous system.s reserved.
Table 1
Demographic and clinical data in 112 nonobese type 2 diabetes patients and 66
controls.
Nonobese type 2
diabetes patients
Controls p
Age, years 63  5 62  6 ns
Sex, % male 62% 61% ns
BMI, kg/m2 28  2 27  2 ns
Orthostatic Grading Scale 7  5 5  4 <0.01
ESS score 11  2 4  2 <0.05
Poor sleep, chronic % 45% 15% <0.01
Nocturnal awakening % 59% 23% <0.01
Sleepiness % 48% 10% <0.01
Snoring % 38% 37% ns
Fatigue % 45% 10% <0.01
BMI, body mass index; ESS, Epworth Sleepiness Scale; ns, not signiﬁcant, p  0.05.
Data presented as mean  standard deviation (SD), level of signiﬁcance p < 0.05.
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cohort of diabetes type 2 non-obese patients and compare it with age-
and sex-matched patients with other disorders seeking help at two
different hospital services. We hypothesized that diabetes type 2 pa-
tients would presentmore sleep alterations than nondiabetic patients.
Methods
Patients
A group of 112 non-obese consecutive patients with type 2 dia-
betes were compared with a control group of 66 patients with other
disorders who volunteered participating in the study and were age-,
sex- and body mass index (BMI)-matched with the patients with
diabetes. Patients and controls were consecutively recruited during
the period January 2011eMay 2012 from either the emergency
department of the C. Cantù Hospital, Abbiategrasso, Milan, Italy
(N¼ 71, 39 women, mean age, 56; standard deviation [SD], 21), or the
pulmonary disorders unit of the Luigi Sacco Hospital, Milan (N¼ 41,19
women, mean age, 51; SD,18). All patients with diabetes were treated
with metformin in the range of 500e1500 mg/day. Patients were
included no matter whether they reported sleep problems or not.
Exclusion criteria comprised history of neurological or psychi-
atric disorders, alcohol or drug abuse, chronic renal failure or ure-
mia, large ﬁber polyneuropathy (as assessed through standard
nerve conduction studies), rheumatoid arthritis, anemia, hypothy-
roidism, chronic obstructive pulmonary disease, heart disease, liver
cirrhosis, and B12 deﬁciency. This aimed to exclude that these
conditions could affect peripheral nerve transmission, and obesity
(BMI  30), that could affect sleep and be a risk factor for OSA.
Patients and controls were excluded if they were taking any drug
that could affect sleep quality, such as the hypoglycemia-inducing
antidiabetics insulin and sulfonylureas. To rule-out the presence
of the above, all patients were subjected to neurological examina-
tion, blood chemistry and urinalysis, and lower limb standard nerve
conduction. The adopted cut-off for each measure was 46 m/s for
motor nerve conduction velocity (MNCV) of both peroneal nerves,
5 mV for compound muscle action potential (CMAP) of both
peroneal and tibial nerves, 6 mV for sensitive amplitude potential
of both sural nerves, and 48 m/sec for sensory nerve conduction
velocity (SNCV) of both sural nerves [2].
Before performing polysomnography (PSG), all participants
were asked to identify the most likely factors contributing to sleep
complaints and ﬁlled-out the Epworth Sleepiness Scale (ESS) [14].
To assess the degree of autonomic dysfunction, all participants
completed the Orthostatic Grading Scale (OGS), a ﬁve-item self-
reported questionnaire [33]. Patients were asked to grade each item
on a Likert scale ranging 0 to 4, with 0 being the lowest and 4 the
highest. The total OGS score was the sum of scores on each item.
Higher scores indicate greater severity of autonomic dysfunction.
The polysomnographic (PSG) equipment combines electroen-
cephalogram, electro-oculogram, electrocardiogram, sub-mental
and tibial electromyogram, body movement assessment, nasal
and oral airﬂow, respiratory effort via thoracic and abdominal
bands (Alice 3; Healthdyne, Marietta, OH), and oximetry pulse rate
(Pulsox 7 Minolta, Osaka, Japan).
The performing PSG was performed in our sleep laboratory, a
sound-attenuated room with temperature control. Patients were
required to maintain their daily routine habits, including diet and
therapeutic drug intake; they were asked to allow 2 h after dinner
before going to bed, which was about 23.00 for all patients. Sleep
time was free, but had to be at least 300 min.
OSA was identiﬁed as the cessation of airﬂow 10 s with
continued chest and abdominal movement. Hypopnea was identi-
ﬁed as a30% reduction in airﬂow accompanied by a 4% decrease inoxygen saturation and/or followed by arousal, with continued chest
and abdominal movement [12]. Obstructive Apnea-Hypopnea In-
dex (AHI) was deﬁned as the number of obstructive apneas or
hypopnea per hour of sleep.
Participants with an AHI >5 were deﬁned as having OSA [46].
To qualify as PLMs, leg movements had to last 0.5e10 s, to recur
every 5e90 s, and to occur in a series of at least four such move-
ments in a row that are at least 8 mV in amplitude [12]; periodic
movements with close temporal relation to apnea or hypopnea
were not interpreted as PLMs. A PLM index (numbers of PLMs per
hour of sleep) > 5 was considered to be pathological [23].
When PLM index was >20, with associated excessive daytime
sleepiness (ESS score 9), and a subjective feeling of nonrestorative
or disturbed sleep, a periodic limb movement disorder during sleep
(PLMD) was diagnosed [12].
Arousal was scored according to the American Academy of Sleep
Medicine criteria [12].
Bed-time and awakening time were at each participant’s
discretion and PSG was terminated after ﬁnal awakening. To avoid
the ﬁrst-night effect, each participant spent two nights in the sleep
laboratory; only data recorded during the second night were
evaluated.
The study was approved by the hospital’s medical ethics com-
mittee. Informed consent was obtained from all participants.
Statistical analysis
The data were analyzed using the Statistical Package for the
Social Sciences, version 20 (IBM SPSS Statistics 20, 2011) and
expressed as mean and standard deviation. Statistical analysis of
the anthropometric data and polysomnographic recordings was
performed using unpaired Student’s t test. Pearson’s chi-square
goodness of ﬁt was used for other comparisons of means and
proportions. Comparison of multiple groups was performed by one-
way analysis of variance (ANOVA1-way). Spearman’s rank correla-
tion has been used as appropriate.
The level of signiﬁcance was set at P < 0.05.
Results
In our study a high proportion of non-obese type 2 diabetes
patients (69%, 78 out of 112) had sleep disorder; of these, 13 out of
78 (16%) were affected by OSA and 65 (84%) by PLMs. Twenty-ﬁve of
the 65 patients with PLMs (38%) met criteria for PLMD.
Table 1 compares demographic and clinical data of type 2 dia-
betes patients with controls, including the most common sleep
complaints, i.e., nocturnal awakening (59%; p < 0.01), poor sleep
Table 2
Sleep values in 112 nonobese type 2 diabetes patients and 66 controls.
Nonobese type 2
diabetes patients
Controls p
Sleep time, min 312  50 400  46 <0.001
Sleep efﬁciency, % 78  8 88  7 <0.01
nREM stage 1, % sleep time 12  6 13  5 ns
nREM stage 2, % sleep time 41  6 40  8 ns
nREM slow wave, % sleep time 12  5 21  6 <0.01
REM, % sleep time 10  5 16  3 <0.01
AHI, number/hour 5  4 4  1 ns
Arousal index, number/hour 15  7 4  1 <0.001
PLM index, number/hour 18  8 3  2 <0.001
AHI, apnea-hypopnea index; nREM, nonREM; ns, not signiﬁcant, p  0.05; PLM,
periodic limb movement; REM, rapid eye movement.
Data presented as mean  SD, level of signiﬁcance p < 0.05.
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p < 0.01), and for scores on the two scales (ESS, p < 0.05; OGS,
p < 0.01).
In diabetes patients, sleep time (p < 0.001), sleep efﬁciency
(sleep-time/time in bed) (p < 0.01), and the proportions of REM
sleep and non-REM slow wave sleep to total sleep time (p < 0.01)
were signiﬁcantly lower, while the arousal index and the PLM index
were signiﬁcantly greater (p < 0.001) compared to controls
(Table 2).
Sleep disorder measures and indexes, as expected, distinguished
between non-obese type 2 diabetes patients with OSA, PLMs, and
PLMD on one hand and those without sleep disorder, on the other;
the latter did not differ from controls on these measures (Table 3).
Diabetes type 2 patients with sleep disturbance scored higher
than both patients with diabetes type 2 patients without sleep
disturbance and controls on the OGS (Table 4). OGS scores were
signiﬁcantly correlated with the arousal and PLN indexes in OAS,
PLMs and PLMD patients with diabetes type 2, while in the OAS
group correlated signiﬁcantly also with AHI (Table 5).
Discussion
In this study we found a high prevalence of sleep disorders in
group of nonobese type 2 diabetes patients, with only 22% having a
sleep architecture comparable to controls. Thus we conﬁrmed our
hypothesis that patients with diabetes type 2 patients would have
more deranged sleep than nondiabetic patients. While this is not
surprising, because also others have shown that more than half of
diabetic samples present sleep complaints [21] and that sleep dis-
orders are a risk factor for type 2 diabetes [17], it remarkably
occurred in our sample of patients with type 2 diabetes in the face
of metformin treatment, which is known to positively affect sleep
duration and quality [15].Table 3
Sleep values in 112 nonobese type 2 diabetes patients, with OSA, PLMs, PLMD and witho
OSA (N ¼ 12) PLMs (N ¼ 40)
Sleep efﬁciency, % 71  6* 78  8*
nREM stage 1, % sleep time 12  6 12  9
nREM stage 2, % sleep time 39  6 39  8
nREM slow wave, % sleep time 10  5* 15  4*
REM, % sleep time 11  4* 12  2*
AHI, number/hour 15  5** 3  2
Arousal index, number/hour 16  6** 13  2**
PLM index, number/hour 7  3* 15  3**
AHI, apnea-hypopnea index; nREM, nonREM; ns, not signiﬁcant, p  0.05; OSA, obstru
disorder; PLMs, periodic limb movements during sleep; REM, rapid eye movement; WSD
Data presented as mean  SD, level of signiﬁcance p < 0.05.
Post hoc: *p < 0.05, **p < 0.01, ***p > 0.001 comparison between nonobese type 2 diabIn the group of patients with sleep disturbance, the prevalence
of both OSA (15%) and PLMs (84%) was higher than in the general
population of the same age, which is respectively 1e5% for OSA and
44% for PLM [12]. Our results conﬁrm previous ﬁndings [3,19,31].
The reasons why OSA can occur in non-obese type 2 diabetes
patients are not clear. While OSA is related to central obesity, which
in turn predisposes to insulin resistance [13,29], it is also possible
that diabetic autonomic neuropathy may cause increased OSA
[7,44].
OGS scores conﬁrm the presence of an autonomic disorder in
those diabetic patients who have sleep disorders. Several reasons
might underlie the occurrence of OSA and PLMs in patients with
autonomic neuropathy.
The ﬁrst reason is that autonomic neuropathy is often associated
with peripheral sensory neuropathy [32]. Since the patency of the
pharyngeal airway depends on the activity of various dilator mus-
cles, which are controlled by central and peripheral respiratory
neurons that coordinate inspiratory muscle activity through che-
moreceptors, vagal input, and sleep [26,43,45], any imbalance in
this delicate control system may impair airway patency and lead to
OSA. In fact [18], reported impaired temperature sensitivity in the
oropharynx of patients with OSA and speculated that sensory
neuropathy may reduce upper airway patency during sleep, thus
leading to airway collapse and OSA.
Secondly, central catecholamine systems seem to play an
important role in the generation of PLMs [42]. Sympathetic acti-
vation occurs periodically in the setting of the physiological sleep-
wake control; once it exceeds a certain threshold, it triggers or
facilitates PLMs. Thus the magnitude and frequency of movements
would depend on the magnitude and frequency of the sympathetic
oscillation [9]. The sympathetic nervous system is also involved in
the generation of sensory discomfort which accompanies PLMs [4].
In this study we excluded large-ﬁber neuropathy. Nevertheless,
some of our dysautonomic patients could possibly have peripheral
neuropathy.
The possible involvement of extrapyramidal motor network
dysfunction has been suggested, with periodic sympathetic acti-
vation that may induce PLMs [4]. Gallego et al. [8] showed that the
dopamine content of diabetic rats was reduced in several areas of
the central nervous system, including the striatum and midbrain.
Based on these considerations [22], suggested that PLMs could be
caused by the combination of decreased dopaminergic control and
increased excitatory nociceptive input, the latter due to neuropathic
sensitization of peripheral sensory neurons.
The latest pathogenic hypothesis of both PLMs and its related
disorder, restless leg syndrome, suggests the primary role of
sympathetic-dopaminergic imbalance within the dorsal horn of the
spinal cord, due to a deﬁcit of the A11 dopaminergic diencephalo-
spinal pathway, which would be unable to inhibit the sympatheticut sleep disorders vs. 66 controls.
PLMD (N ¼ 25) WSD (N ¼ 34) Controls (N ¼ 66) p
70  7* 87  7 88  7 <0.001
12  9 13  6 13  2 ns
40  5 39  7 39  8 ns
10  6* 20  9 21  6 <0.001
9  5* 15  8 16  3 <0.001
3  1 5  1 4  1 <0.05
16  3** 4  1 4  1 <0.001
28  4*** 3  2 3  2 <0.001
ctive sleep apnea; PLM, periodic limb movement; PLMD, periodic limb movement
, without sleep disorders.
etes patients vs. controls.
Table 4
Clinical data in 112 nonobese type 2 diabetes patients, with OSA, PLMs, PLMD and without sleep disorders vs. 66 controls.
OSA (N ¼ 12) PLM (N ¼ 40) PLMD (N ¼ 26) WSD (N ¼ 34) Controls (N ¼ 66) p
ESS score 12  3** 6  3 11  2** 5  2 4  2 <0.001
Orthostatic grading scale 9  5* 6,9  5* 7,3  5* 5.1  5 5  4 <0.01
Chronically
poor sleep, %
60%** 16% 63%** 15% 15% <0.001
Nocturnal awakening, % 63%** 25% 58%** 22% 23% <0.001
Sleepiness, % 60%** 20%* 45%** 10% 10% <0.001
Snoring, % 35% 36% 35% 36% 35% ns
Fatigue, % 55%** 21%* 50%** 12% 10% <0.01
ESS, Epworth Sleepiness Scale; ns, not signiﬁcant, p  0.05; OSA, Obstructive sleep apnea; PLMD, periodic limb movement disorder; PLMs, periodic limb movements during
sleep; REM, rapid eye movement; WSD, without sleep disorders.
Data presented as mean  SD, level of signiﬁcance p < 0.05.
Post hoc: *p < 0,05, **p < 0,01, ***p < 0.001; comparison between nonobese type 2 diabetes patients vs. controls.
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the autonomic disorder, as reﬂected by OGS score, indicate a defec-
tive pattern of sympathetic activity (orthostatic hypotension), and
not the releaseof sympathetic activation fromdopaminergic control.
However [5], induced a neuropathic postural tachycardia syndrome
through partial lesions of the adrenergic autonomic nervous system
in an animal experiment; these authors proposed a b-adrenergic
supersensitivity as a possible adaptive mechanism, supporting a
potential role for adrenal medullary compensation. In diabetic pol-
yneuropathy, a range of ﬁber damagemayarise, involving both large
myelinated and small unmyelinated ﬁbers. We may speculate that
the variable combination of both neuropathic peripheral sensory
afferent pathway sensitization and dopamine-noradrenaline
imbalance in the intermedio-lateral nuclei of the spinal cord is
required for PLMs to occur andmight account for the wide diffusion
of PLMs in diabetic patients.
Poor sleep quality may cause considerable daytime sleepiness
and fatigue in diabetic patients. In fact, among our non-obese type 2
diabetic patients, those with OSA and PLMs show more deranged
sleep architecture and more prominent daytime symptoms.
Limitations
The comparison group amounted to about half the size of the
experimental sample; furthermore, we adopted the OGS ques-
tionnaire to assess autonomic dysfunction, rather than a more ac-
curate measurement method as, for instance, spectral analysis of
heart rate variability (HRV) [11], but the need to assess a large
sample with the minimum burden possible, and time restriction at
the emergency department, dictated our choice. However, the ac-
curacy of the OGS is widely accepted in assessing orthostatic hy-
potension. The latter, in turn, is one of the main clinical
manifestations of diabetic dysautonomy, i.e., cardiac autonomic
neuropathy (CAN) [28]. Though HRV tests are the most sensitive,
orthostatic hypotension assessment is the most speciﬁc forTable 5
Spearman’s rank correlation in nonobese type 2 diabetes patients, with OSA, PLMs,
and PLMD.
OSA (N ¼ 12) PLMs (N ¼ 40) PLMD (N ¼ 26)
Orthostatic
Grading
Scale vs.
Arousal index,
r ¼ 0.60; p < 0.05
Arousal index,
r ¼ 0.68; p < 0.001
Arousal index,
r ¼ 0.76; p < 0.001
PLM index, r ¼ 0.56;
p < 0.05
PLM index, r ¼ 0.71;
p < 0.001
PLM index, r ¼ 0.85;
p < 0.001
AHI, r ¼ 0.74;
p < 0.001
AHI, apnea-hypopnea index; OSA, obstructive sleep apnea; PLM, periodic limb
movement; PLMD, periodic limb movement disorder; PLMs, periodic limb move-
ments during sleep; r, Pearson’s correlation coefﬁcient; level of signiﬁcance,
p < 0.05.evaluating the presence of CAN [34]. Furthermore, the sample was
heterogenous, in that it was derived from two different units, one of
which was an emergency department; this might have somehow
biased our results, because emergency situations usually affect
sleep negatively. Moreover, we did not measure glycosylated he-
moglobin and did not investigate the possible presence of diabetic
retinopathy or nephropathy, upper airway size, lung volumes,
ventilator drive and other measures that could possibly have
affected our results, but the emergency setting did not allow for
thorough patient evaluation.Concluding remarks
Evidence exists for bidirectional interactions between sleep and
the neuro-immune-endocrine circuitry [20]. Sleep, other than
having brain restoration functions, is able to regulate carbohydrate
metabolism, and disordered sleep may result in decreased insulin
sensitivity [36,39]. Partial sleep deprivation may trigger impaired
glucose tolerance, higher evening secretion of cortisol, increased
sympathetic nervous system activity, and reduced leptin secretion
[35], hence producing a prediabetic state. In type 2 diabetes pa-
tients, sleep disordersmayworsen autonomic neuropathy, which in
turn was found to be associated with increased mortality [27].
Clinicians whomanage patients with type 2 diabetesmust be aware
of the increased likelihood of sleep disturbance and investigate
thoroughly sleep-related symptoms along with autonomic neu-
ropathy. The suspected presence of sleep disorder should prompt
performance of PSG, because an adequate treatment could
normalize sleep architecture and efﬁciency, improving both quality
of life and possibly control the diabetic condition.References
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